MyBiotics Pharma LTD

What MyBiotics Pharma LTD does

MyBiotics Pharma LTD is a clinical-stage microbiome therapeutics company founded in 2014 and headquartered in Herzliya, Israel. The company develops live biotherapeutic products using four proprietary technology platforms: MyCrobe™ (single-strain fermentation and formulation engineered for survival under GI, bile, acid, heat, and antibiotic conditions), SuperDonor™ (whole microbiome production and recovery from donor samples, positioned as a standardized alternative to fecal microbiota transplantation), SuperDonor Select™ (multi-strain co-culture for hard-to-grow anaerobes and personalized consortia), and MyLiveIn (a computational AI platform supporting artificial donor bio-bank design, predictive microbiome screening, and preclinical evaluation of complex communities). MyBiotics claims to be the world's first producer of an artificial donor biological bank, which it markets as a differentiator against existing probiotics with low clinical impact and donor-dependent FMT.

The company's product pipeline spans infectious disease (MBX-SD-202 for recurrent C. difficile infection, Phase 1 completed January 2022; MBX-SD-201 for acute CDI), gastrointestinal health (MBX-MC-101 for acute dysbiosis), women's health/bacterial vaginosis (co-developed with Ferring Pharmaceuticals and Rebiotix), immuno-oncology (microbiome combinations to enhance anti-PD-1/PD-L1 response in melanoma, with Hadassah Medical Center), metabolic disease/NASH (with Galmed Pharmaceuticals around Aramchol), dermatology/skin microbiome (with Mii Fund and Maruho Co. Ltd.), and next-generation probiotics for consumer segments. The core asset is an encapsulated oral whole-microbiome drug candidate; supporting indications target large addressable markets with documented unmet need.

MyBiotics operates a traditional clinical-stage pharmaceutical go-to-market model: advance candidates through Phase I/II/III, then commercialize via licensing and co-development partnerships with pharmaceutical companies. Direct revenue today consists of non-dilutive grants (€2.0M EU Horizon 2020 award, October 2020) and licensing/option payments from collaborators; no commercial product sales exist. Strategic shareholders and partners include AnGes (lead investor in the $8M 2018 round), Mii Fund (lead investor in the $3.5M 2021 round, partnered with Japan's Maruho), Ferring Pharmaceuticals/Rebiotix (multi-year women's health collaboration since 2017), Hadasit/Hadassah Medical Center, and Galmed Pharmaceuticals. The company is privately held with 11–50 employees.

Name

MyBiotics Pharma LTD

Legal name

MyBiotics Pharma LTD

Website

https://mybiotics-pharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Microbiome Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

akta.pro secondary industries

Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD), Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE), Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Live biotherapeutic products
• Microbiome therapeutics
• Whole microbiome technology
• Probiotic supplements
• Microbial fermentation platforms

Headquarters

HQ city

Rehovot

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Live Biotherapeutic Products: Revenue from development and commercialization of live biotherapeutic drugs targeting infectious diseases (C. difficile infection), women's health, gastro, and oncology indications. Currently in clinical stage with Phase 1 trial completed for MBX-SD-202.
2. Licensing Royalties: Multi-year strategic collaborations with pharmaceutical companies like Ferring Pharmaceuticals include option and license agreements generating upfront payments and potential milestone/royalty payments upon successful development and commercialization.
3. Probiotic Supplements: Revenue from supplements and food products using proprietary MyCrobe and SuperDonor Select technologies for improved bacterial viability, stability, and colonization in non-pharmaceutical markets including supplements, food, skin, and animal health.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MyBiotics Pharma develops clinical-stage live biotherapeutic products and microbiome-based therapeutics using proprietary single-strain, whole-microbiome, and multi-strain fermentation/culturing technologies integrated with an AI discovery platform. Its portfolio targets C. difficile infection, women's health, immuno-oncology, and metabolic disorders, with additional probiotic supplements and food applications.

Product overview

MyBiotics Pharma is a clinical-stage microbiome therapeutics company developing live biotherapeutic products based on four integrated technology platforms: MyCrobe (single strain fermentation), SuperDonor (whole microbiome recovery), SuperDonor Select (multi-strain co-culture), and MyLiveIn (computational AI discovery). The company's product portfolio includes clinical-stage drug candidates MBX-SD-202 and MBX-SD-201 for C. difficile infection, MBX-MC-101 for dysbiosis, plus pipeline products targeting women's health/bacterial vaginosis, immuno-oncology, NASH, and next-generation probiotics. The integrated platform enables development from single strains through complex microbial consortia to whole microbiome-based products, all supported by AI-enabled design and screening capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• MyCrobe: Single strain fermentation and formulation technology for live bacteria culturing, delivery and colonization.
• SuperDonor
• SuperDonor Select
• MyLiveIn

Products and services

• MBX-SD-202 Whole microbiome treatment based on SuperDonor technology for treating recurrent Clostridioides difficile infection (CDI). Developed as an oral encapsulated investigational drug using standardized whole microbiome culturing from donor samples.
• MBX-SD-201 Whole microbiome product candidate for treating acute CDI based on SuperDonor technology, positioned as a potential first scalable alternative to fecal microbiota transplantation (FMT).
• MBX-MC-101 Single strain probiotic product based on MyCrobe technology for antibiotics-associated diarrhea and acute dysbiosis, available in tablet and pill formulations.
• Women's Health Bacterial Vaginosis Program Live microbiota-based biotherapeutic product under development for bacterial vaginosis, a common vaginal infection linked to miscarriage and pregnancy complications. Uses MyCrobe technology for restoring vaginal microbiome equilibrium; being co-developed with Ferring Pharmaceuticals and Rebiotix.
• Immuno-Oncology Microbiome Program Microbiome-based therapeutic product under development for improving cancer immunotherapy response, specifically targeting PD-1/PD-L1 checkpoint inhibitors for melanoma patients, in collaboration with Hadassah Medical Center.
• NASH/Fibrosis Microbiome Program Standalone microbiome-based treatment under development for non-alcoholic steatohepatitis (NASH) and fibrosis, in collaboration with Galmed Pharmaceuticals for use with Aramchol.
• Next Generation Probiotics Next generation probiotic products under development using SuperDonor Select technology for personal and functional use applications such as sports, babies, and other targeted consumer segments.

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Hadasit Medical Research Services and Development Ltd.coreStrategic or Co-development Partner · 6 April 2021Two-year research collaboration and licensing agreement with Hadassah Medical Center for identification of microbiome-based therapeutics to enhance response to anti-PD-1 and anti-PD-L1 checkpoint inhibitors in melanoma patients. Combines Hadassah's immunotherapy expertise with MyBiotics' proprietary microbiome technologies. MyBiotics has exclusive license for all data and inventions stemming from collaboration.
• Ferring PharmaceuticalscoreStrategic or Co-development Partner · 17 February 2021Multi-year strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis, a common vaginal infection among women of reproductive age. Combines MyBiotics' culturing, delivery and colonisation technologies with Ferring's therapeutic development and commercial expertise. Builds on existing collaboration initiated in 2017. This is Ferring's first non-donor derived formulation and first live microbiota-based product specific to reproductive medicine.
• Rebiotix Inc.coreStrategic or Co-development Partner · 17 February 2021Rebiotix, a Ferring Company, contributes expertise in developing clinical-stage live microbiota-based biotherapeutic products built on its pioneering MRT drug platform. Collaboration leverages Rebiotix's world-leading development experience with MyBiotics' MyCrobe live bacteria culturing, delivery and colonisation technology for women's health applications.
• Galmed Pharmaceuticals Ltd.minorStrategic or Co-development Partner · 9 November 2020R&D collaboration agreement to identify and optimize selected microbiome repertoire associated with response to Aramchol (NASH treatment). Research focuses on development of standalone microbiome-based treatment for NASH and fibrosis. Galmed is listed on NASDAQ (GLMD).
• Ferring Holding Ltd.coreOEM/ Whitelabel/ Licensing Partner · 5 March 2018Second option agreement for validation of MyBiotics' microbiome-based therapeutics in women's health field. Follows first agreement signed in June 2017 for validation of technology in treatment of non-disclosed gastroenterology condition.

Scale indicators2 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Seres Therapeutics: Seres is a clinical-stage microbiome therapeutics company with approved/advanced programs in recurrent C. difficile infection (VOWST). It is the most advanced direct competitor to MyBiotics' CDI franchise and sets the regulatory/commercial benchmark.
• Finch Therapeutics: Finch develops microbiome therapeutics derived from whole microbial communities using its FINCH platform. Although it has faced clinical setbacks, it remains a relevant reference for whole-microbiome therapeutic development similar to MBX's SuperDonor.
• 4D pharma: 4D pharma develops single-strain and defined-consortium live biotherapeutics across oncology, respiratory, and gastrointestinal indications. Its MicroRx platform and live biotherapeutic pipeline directly overlap with MBX's MyCrobe single-strain platform.
• Rebiotix (Ferring): Rebiotix, a Ferring company, is a pioneer in live microbiota-based biotherapeutics (MRT drug platform) and is a direct collaborator of MyBiotics in the women's health program. It directly competes in CDI and is a key reference point for MBX's whole-microbiome positioning.
• Vedanta Biosciences: Vedanta develops defined consortia of bacterial strains as live biotherapeutics across CDI, immuno-oncology, and inflammatory bowel disease. Its rationally designed consortium approach directly overlaps with MBX's SuperDonor Select and AI-driven consortium design.
• MaaT Pharma: MaaT Pharma develops microbiome-based therapies for oncology and graft-versus-host disease using pooled donor microbiota. Its whole-microbiome approach and oncology focus are closely analogous to MBX's SuperDonor and immuno-oncology programs.
• BiomX: BiomX develops phage- and microbiome-based therapeutics with programs in inflammatory bowel disease, oncology support, and skin disorders. It overlaps with MBX on microbiome-based therapeutic development and the dermatology/skin microbiome angle with Maruho.

Emerging players

• Assembly Biosciences: While primarily focused on antiviral therapies, Assembly Bio has invested in microbiome-adjacent programs; it represents an adjacent biotherapeutics peer with overlapping R&D capabilities relevant to MBX's biotherapeutic platform.
• Eligo Bioscience: Eligo develops precision microbiome medicines using engineered phage and synthetic biology approaches. It represents an emerging next-generation microbiome therapeutics peer using synthetic biology methodologies that are adjacent to MBX's engineered consortia direction.
• Second Genome: Second Genome applies microbiome science to drug discovery and development in inflammation and metabolic disease. Its AI-driven microbiome discovery approach overlaps with MBX's MyLiveIn computational platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mybiotix-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MyBiotics Pharma LTD